查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1439210

全球傳染病診斷市場評估:按產品類型、按樣本類型、按設定、按測試類型、按適應症、按最終用戶、按地區、機會、預測（2017-2031）

Infectious Disease Diagnostics Market Assessment, By Product, By Sample Type, By Setting, By Type of Testing, By Indication, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 225 Pages | 商品交期: 3-5個工作天內

價格

全球傳染病診斷市場規模預計將從 2023 年的 277.8 億美元成長到 2031 年的 448.5 億美元，預測期內複合年增長率為 6.17%。

由於傳染病流行的增加、多樣化診斷測試的可用性以及對即時診斷測試技術的日益偏好等因素，傳染病診斷市場預計將成長。 主要參與者創新疾病診斷和監測技術的市場開發也為市場擴張做出了重大貢獻。 增加對改善疾病模型分析和關鍵參與者策略活動的投資也有助於市場成長。

傳染病疫情蔓延

進入 21 世紀以來，傳染病呈上升趨勢，COVID-19、SARS 和豬流感等流行病對全世界人類的生命和生計造成了毀滅性影響。 傳染病疫情的蔓延與傳染病診斷解決方案的需求成正比，進一步擴大了市場。 傳染病是全世界死亡的主要原因之一，有效的診斷可以有效地使用適當的治療計劃。

各種診斷測試的可用性

傳染病有多種診斷測試，包括實驗室測試、快速診斷測試、血清學測試和聚合□鏈反應 (PCR) 測試。 這些測試可以檢測抗體、抗原和某些微生物，以幫助診斷感染。 實驗室檢驗使用血液、尿液、痰和其他體液樣本，透過染色、培養和分子生物學技術來鑑定微生物。 快速診斷測試有多種形式和平台，可快速提供結果以幫助臨床決策並實現護理點管理。 血清學檢測尋找抗體來確認過去的暴露情況，PCR 測試則檢測微生物的遺傳物質。 這些多樣化的檢測方法對於傳染病的準確、及時診斷發揮重要作用。

亞太地區是成長最快的地區

亞太地區傳染病疫情正在加劇。 這是由於貧窮、人口過剩、預防性衛生系統不足和人口成長等因素所造成的。 該地區是新興傳染病的熱點地區，據報導出現了新的霍亂和登革熱菌株。 儘管衛生和醫療基礎設施有了顯著改善，但傳染病仍然是該地區主要的死亡原因，而且由於氣候和經濟原因，傳染病在東南亞的流行率尤其高。

本報告調查了全球傳染病診斷市場，提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構以及影響市場成長的因素。我們編制分析、案例研究、競爭景觀、主要公司簡介等等。

目錄

第一章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第四章全球傳染病診斷市場展望

  • 市場規模/預測
  • 按產品
    • 試劑、試劑盒和消耗品
    • 設備
    • 軟體
  • 依樣本類型
    • 血液/血液成分
    • 尿液
    • 其他
  • 透過設定
    • 臨床檢查
    • 即時偵測
  • 按檢定類型
    • 分子測試
    • 血清學檢測
    • 抗原檢測
    • 文化測試
    • 驗血
    • 影像檢查
  • 依指示
    • 細菌感染
    • 病毒感染
    • 中樞神經系統感染
    • 心血管感染
    • 真菌感染
    • 胃腸道感染
    • 性傳染病
    • 其他
  • 按最終用戶
    • 診斷實驗室
    • 學術機構/醫療機構
    • 醫院
    • 門診
    • 家庭醫療護理
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 各公司的市佔率

第五章全球傳染病診斷市場展望:依地區劃分

  • 北美
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第 6 章市場映射

  • 按產品
  • 依樣本類型
  • 透過設定
  • 按檢定類型
  • 依指示
  • 按最終用戶
  • 按地區

第七章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 抑製成長的因素（問題、限制因素）

第 9 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/最新技術

第十章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（5 家參與公司）

第11章價格分析

第 12 章案例研究

第十三章主要公司展望

  • Becton Dickinson & Company
  • Cepheid Inc.
  • Abbott Laboratories
  • BioMerieux SA
  • Hologic Inc.
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • DiaSorin SpA
  • F. Hoffmann-La Roche AG

第 13 章策略建議

第十五章關於我們公司/免責聲明

Product Code: MX11046

Global infectious disease diagnostics market is projected to witness a CAGR of 6.17% during the forecast period 2024-2031, growing from USD 27.78 billion in 2023 to USD 44.85 billion in 2031F. Infectious disease diagnostics involve the identification of the causative agent of an infectious disease, such as bacteria, viruses, fungi, or parasites, in a patient with a compatible clinical illness. The process is essential for determining the most effective treatment. Diagnostic methods include laboratory tests, such as blood, urine, and tissue samples, as well as imaging scans to reveal evidence of the microbe causing the disease. The detection of the pathogen can be done through cultivation, isolation in cell culture, and identification biochemically, antigenically, or genetically. Additionally, specific immune responses and molecular technologies are used for accurate diagnosis, especially in low-resource settings.

The infectious disease diagnostics market is expected to thrive under the influence of factors like growing prevalence of infectious diseases, availability of a diverse range of diagnostic tests, and the increasing preference for point-of-care diagnostic testing techniques. The development of innovative disease diagnosis and monitoring technologies by key players in the industry is greatly contributing to the expansion of the market. Increasing investments for improving disease model analysis, and the strategic activities of key players is also contributing to the market growth.

However, the growth of infectious disease diagnostics market may be hindered by a lack of awareness of novel diagnostic solutions, absence of compiled regulatory guidelines, and lower positivity rates due to inferior laboratory conditions. Market players are actively involved in strategic product launches and business tactics to expand the market.

In February 2023, Thermo Fisher Scientific recently announced the release of Applied Biosystems TaqPath PCR kits designed specifically for diagnosing infectious diseases. These kits are effective in detecting diseases such as Multi-Drug Resistant Tuberculosis (MDR-TB), M. Tuberculosis complex (MTB), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human Immunodeficiency Virus (HIV). Moreover, they can be used for genetic analysis (HLA B27). The Central Drugs Standard Control Organization (CDSCO) has approved these kits, and they will be produced in India in partnership with Mylab Discovery Solutions, a leading healthcare company.

Growing Prevalence of Infectious Diseases

Infectious diseases have been on the rise in the 21st century, with outbreaks such as COVID-19, SARS, and swine flu with a devastating impact on lives and livelihoods globally. Factors contributing to the emergence and spread of infectious diseases include ecological, environmental, or demographic factors that place people in increased contact with a previously unfamiliar microbe, as well as increasing prevalence of these factors. The growing prevalence of infectious diseases is directly proportional to the demand for infectious disease diagnostic solutions, further expanding the market. Infectious diseases are one of the leading causes of death globally and a suitable treatment plan be effectively utilized through efficient diagnostics.

According to the World Economic Forum, annually, infectious diseases, such as malaria, HIV, and tuberculosis, are the cause of death for over 2.8 million people, and more than 1.7 billion people require treatment for at least one neglected tropical disease, globally. In addition, epidemic-prone infectious diseases such as COVID-19 and Ebola are anticipated to claim thousands to millions of lives before control and preventive measures can be effective.

Availability of a Diverse Range of Diagnostic Tests

A diverse range of diagnostic tests is available for infectious diseases, including laboratory tests, rapid diagnostic tests, serological testing, and polymerase chain reaction (PCR) testing. These tests can detect antibodies, antigens, and specific microorganisms to aid in the diagnosis of infectious diseases. Laboratory tests use samples of blood, urine, sputum, or other fluids to identify microorganisms through staining, culturing, or molecular methods. Rapid diagnostic tests, which are available in various formats and platforms, provide rapid results to inform clinical decision-making and enable point-of-care management. Serological testing looks for antibodies to verify previous exposure, while PCR testing detects the genetic material of microorganisms. These diverse testing methods play a crucial role in accurate and timely diagnosis of infectious diseases. The diverse range is anticipated to contribute to the expansion of the market. Market players offer a variety of rapid diagnostic kits for different diseases.

In July 2023, EMPE Diagnostics launched mfloDx MDR-TB test kit for rapid diagnosis of tuberculosis and antibiotic resistance. The mfloDx MDR-TB test kit, developed in Genome Valley, provides clear yes/no results in a fraction of the time compared to traditional methods. It's recognized by the World Health Organization and approved by the Central Drugs Standard Control Organization, poised to change tuberculosis diagnostics globally.

Dominance of Laboratory Testing Segment While Fast Growth for PoC Testing

The laboratory testing segment is expected to lead the market with a larger value share throughout the assessment period due to its widespread application areas and efficacy percentage. Clinical laboratory tests encompass a wide range of services, such as complete blood count, basic metabolic panel, genetic testing, and clinical chemistry. While point-of-care testing is anticipated to grow at a higher CAGR owing to the rising rate of adoption of such technologies in diagnostics and the increasing availability of rapid diagnostics test kits. The growth in point-of-care testing is driven by factors like the increased demand for at-home testing and the development of innovative services, including personalized medication selection and dosing based on genetic testing. Market participants are dedicated to expanding their point-of-care portfolio through the launch of new rapid test kits.

For instance, in June 2023, Agdia, Inc. launched a new rapid and field-deployable RNA-based assay to detect Blueberry scorch virus (BlScV). The test has outperformed all commercially available serological (ELISA) tests and matches the performance of the most well-established PCR methods presently in use. The rapid diagnostic kit is called AmplifyRP XRT for BlScV.

Molecular Tests to Dominate the Market

The molecular tests segment is anticipated to dominate the infectious disease diagnostics market. Molecular diagnostics, including techniques such as DNA microarray analysis, is one of the fastest-growing areas in infectious disease identification. Molecular diagnostics is a modern solution for detecting parasitic, bacterial, and viral infections. Unlike traditional testing methods, these tests are more advanced and overcome the drawbacks of manually prepared media, longer turnaround duration, and poor sensitivity. They are highly accurate and reliable, making them an essential tool in the field of medical diagnosis.

For instance, in November 2023, Roche launched the LightCycler PRO System which uses the reliable technology of the LightCycler Systems that preceded it. The new system offers better performance and is more user-friendly, while bridging the gap between translational research and in-vitro diagnostics. The LightCycler PRO System is a great addition to Roche's molecular PCR testing portfolio, which includes solutions for various healthcare professionals. These solutions cater to those performing research as well as those testing patients for cancer, infectious diseases, and other public health challenges.

Asia-Pacific to be the Fastest Growing Region

Asia-Pacific is experiencing a growing incidence of infectious diseases. It is due to factors such as poverty, overpopulation, inadequate preventive health systems, and increasing population. The region is a hotspot for emerging infectious diseases, with new variants of cholera and dengue being reported. Despite impressive improvements in health and healthcare infrastructure, infectious diseases remain the major cause of death in the region. The share of deaths due to infectious diseases is increasing in the Asia-Pacific. In the region, Southeast Asia has a higher growth rate due to climatic and economic reasons for the widespread of infectious diseases.

According to the 'Health at a Glance: Asia-Pacific 2022' report published by WHO in 2023, Southeast Asia accounted for the largest number of tuberculosis cases globally in 2020, about 43% of the total cases. Among the countries and territories most affected by tuberculosis in 2020 were India (26.0% of tuberculosis cases globally), China (8.5%), Indonesia (8.4%), the Philippines (6.0%), Pakistan (5.8%), and Bangladesh (3.6%).

Future Market Scenario (2024 - 2031F)

The diagnostic industry is witnessing growing regulatory approvals for infectious disease diagnostic solutions, which are expected to be marketed in near future, further boosting the market. For instance, the Biomedical Advanced Research and Development Authority (BARDA) has supported a diverse portfolio of medical solutions and these products have received a total of 86 FDA approvals, licensures, or clearances. Similarly, the Infectious Diseases Society of America (IDSA) has highlighted the need for new incentives and regulatory changes to spur R&D for new antibiotics and flexible regulations to allow innovative test development to keep pace with emerging infectious diseases. The increasing regulatory approved products for infectious disease diagnosis are anticipated to land the market in future and bring a healthy competition among key players. The FDA has approved a number of diagnostic devices and authorized the emergency use of uncleared devices for infectious diseases, including influenza and respiratory syncytial virus.

In February 2023, The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first over-the-counter (OTC) at-home diagnostic test. This test is capable of detecting and differentiating influenza A and B, commonly known as the flu, and SARS-CoV-2, the virus that causes COVID-19. The Lucira COVID-19 & Flu Home Test is a single-use kit that can be used at home. The test provides results from self-collected nasal swab samples in around 30 minutes.

Key Players Landscape and Outlook

These companies have a strong market presence with a vast product portfolio to offer in the field of diagnostics and research. With the growing infectious disease scenario, these players have strengthened their offerings through collaborations, mergers and acquisitions, and other market tactics.

In April 2023, Biosynex SA announced that it had completed its acquisition of Chembio Diagnostics, Inc. The combination of the two companies' technologies and product portfolios, and the combination of market opportunities, will be important growth drivers for the combined entity. Additionally, significant operational synergies are expected in procurement, research and diagnostics logistics, and production.

In July 2023, Novacyt announced its acquisition of Yourgene Health for approximately EUR 16.7 million (USD 21.2 million) in cash. Yourgene Health, located in Manchester, the United Kingdom, offers a range of molecular diagnostic tests for prenatal screening, male infertility, thrombosis risk, and cystic fibrosis. In addition, the company provides genomic medicine services to healthcare, research, and biopharmaceutical clients.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Infectious Disease Diagnostics Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Product
    • 4.2.1. Reagents, Kits, and Consumables
    • 4.2.2. Instruments
    • 4.2.3. Software
  • 4.3. By Sample Type
    • 4.3.1. Blood and Components
    • 4.3.2. Urine
    • 4.3.3. Other
  • 4.4. By Setting
    • 4.4.1. Laboratory Testing
    • 4.4.2. Point-of-Care Testing
  • 4.5. By Type of Testing
    • 4.5.1. Molecular Tests
    • 4.5.2. Serological Tests
    • 4.5.3. Antigen Tests
    • 4.5.4. Culture Tests
    • 4.5.5. Blood Tests
    • 4.5.6. Imaging Tests
  • 4.6. By Indication
    • 4.6.1. Bacterial Infections
    • 4.6.2. Viral Infections
    • 4.6.3. CNS Infections
    • 4.6.4. Cardiovascular Infections
    • 4.6.5. Fungal Infections
    • 4.6.6. GI Infections
    • 4.6.7. Sexually Transmitted Diseases
    • 4.6.8. Other
  • 4.7. By End-user
    • 4.7.1. Diagnostic Laboratories
    • 4.7.2. Academic And Medical Institutes
    • 4.7.3. Hospitals
    • 4.7.4. Ambulatory Clinics
    • 4.7.5. Home Healthcare
    • 4.7.6. Other
  • 4.8. By Region
    • 4.8.1. North America
    • 4.8.2. Europe
    • 4.8.3. Asia-Pacific
    • 4.8.4. South America
    • 4.8.5. Middle East and Africa
  • 4.9. By Company Market Share (%), 2023

5. Global Infectious Disease Diagnostics Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Product
      • 5.1.2.1. Reagents, Kits, and Consumables
      • 5.1.2.2. Instruments
      • 5.1.2.3. Software
    • 5.1.3. By Sample Type
      • 5.1.3.1. Blood and Components
      • 5.1.3.2. Urine
      • 5.1.3.3. Other
    • 5.1.4. By Setting
      • 5.1.4.1. Laboratory Testing
      • 5.1.4.2. Point-of-Care Testing
    • 5.1.5. By Type of Testing
      • 5.1.5.1. Molecular Tests
      • 5.1.5.2. Serological Tests
      • 5.1.5.3. Antigen Tests
      • 5.1.5.4. Culture Tests
      • 5.1.5.5. Blood Tests
      • 5.1.5.6. Imaging Tests
    • 5.1.6. By Indication
      • 5.1.6.1. Bacterial Infections
      • 5.1.6.2. Viral Infections
      • 5.1.6.3. CNS Infections
      • 5.1.6.4. Cardiovascular Infections
      • 5.1.6.5. Fungal Infections
      • 5.1.6.6. GI Infections
      • 5.1.6.7. Sexually Transmitted Diseases
      • 5.1.6.8. Other
    • 5.1.7. By End-user
      • 5.1.7.1. Diagnostic Laboratories
      • 5.1.7.2. Academic And Medical Institutes
      • 5.1.7.3. Hospitals
      • 5.1.7.4. Ambulatory Clinics
      • 5.1.7.5. Home Healthcare
      • 5.1.7.6. Other
    • 5.1.8. United States*
      • 5.1.8.1. Market Size & Forecast
      • 5.1.8.1.1. By Value
      • 5.1.8.1.2. By Volume
      • 5.1.8.2. By Product
      • 5.1.8.2.1. Reagents, Kits, and Consumables
      • 5.1.8.2.2. Instruments
      • 5.1.8.2.3. Software
      • 5.1.8.3. By Sample Type
      • 5.1.8.3.1. Blood and Components
      • 5.1.8.3.2. Urine
      • 5.1.8.3.3. Other
      • 5.1.8.4. By Setting
      • 5.1.8.4.1. Laboratory Testing
      • 5.1.8.4.2. Point-of-Care Testing
      • 5.1.8.5. By Type of Testing
      • 5.1.8.5.1. Molecular Tests
      • 5.1.8.5.2. Serological Tests
      • 5.1.8.5.3. Antigen Tests
      • 5.1.8.5.4. Culture Tests
      • 5.1.8.5.5. Blood Tests
      • 5.1.8.5.6. Imaging Tests
      • 5.1.8.6. By Indication
      • 5.1.8.6.1. Bacterial Infections
      • 5.1.8.6.2. Viral Infections
      • 5.1.8.6.3. CNS Infections
      • 5.1.8.6.4. Cardiovascular Infections
      • 5.1.8.6.5. Fungal Infections
      • 5.1.8.6.6. GI Infections
      • 5.1.8.6.7. Sexually Transmitted Diseases
      • 5.1.8.6.8. Other
      • 5.1.8.7. By End-user
      • 5.1.8.7.1. Diagnostic laboratories
      • 5.1.8.7.2. Academic and medical institutes
      • 5.1.8.7.3. Hospitals
      • 5.1.8.7.4. Ambulatory clinics
      • 5.1.8.7.5. Home healthcare
      • 5.1.8.7.6. Other
    • 5.1.9. Canada
    • 5.1.10. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Product
  • 6.2. By Sample Type
  • 6.3. By Setting
  • 6.4. By Type of Testing
  • 6.5. By Indication
  • 6.6. By End-user
  • 6.7. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.4.7. Supplier Power
    • 7.4.8. Buyer Power
    • 7.4.9. Substitution Threat
    • 7.4.10. Threat from New Entrant
    • 7.4.11. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 12.1. Becton Dickinson & Company
    • 12.1.1. Company Details
    • 12.1.2. Key Management Personnel
    • 12.1.3. Products & Services
    • 12.1.4. Financials (As reported)
    • 12.1.5. Key Market Focus & Geographical Presence
    • 12.1.6. Recent Developments
  • 12.2. Cepheid Inc.
  • 12.3. Abbott Laboratories
  • 12.4. BioMerieux SA
  • 12.5. Hologic Inc.
  • 12.6. Bio-Rad Laboratories Inc.
  • 12.7. Danaher Corporation
  • 12.8. Thermo Fisher Scientific Inc.
  • 12.9. DiaSorin SpA
  • 12.10. F. Hoffmann-La Roche AG

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

13. Strategic Recommendations

14. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 4. Global Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 5. Global Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 6. Global Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 7. Global Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 8. Global Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 9. Global Infectious Disease Diagnostics Market Share (%), By Region, 2017-2031F
  • Figure 10. North America Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 11. North America Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 12. North America Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 13. North America Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 14. North America Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 15. North America Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 16. North America Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 17. North America Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 18. North America Infectious Disease Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 19. United States Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 20. United States Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 21. United States Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 22. United States Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 23. United States Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 24. United States Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 25. United States Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 26. United States Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 27. Canada Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Canada Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 29. Canada Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 30. Canada Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 31. Canada Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 32. Canada Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 33. Canada Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 34. Canada Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 35. Mexico Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 36. Mexico Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 37. Mexico Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 38. Mexico Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 39. Mexico Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 40. Mexico Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 41. Mexico Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 42. Mexico Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 43. Europe Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 44. Europe Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 45. Europe Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 46. Europe Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 47. Europe Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 48. Europe Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 49. Europe Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 50. Europe Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 51. Europe Infectious Disease Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 52. Germany Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Germany Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 54. Germany Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 55. Germany Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 56. Germany Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 57. Germany Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 58. Germany Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 59. Germany Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 60. France Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. France Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 62. France Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 63. France Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 64. France Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 65. France Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 66. France Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 67. France Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 68. Italy Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 69. Italy Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 70. Italy Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 71. Italy Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 72. Italy Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 73. Italy Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 74. Italy Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 75. Italy Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 76. United Kingdom Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. United Kingdom Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 78. United Kingdom Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 79. United Kingdom Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 80. United Kingdom Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 81. United Kingdom Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 82. United Kingdom Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 83. United Kingdom Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 84. Russia Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 85. Russia Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 86. Russia Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 87. Russia Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 88. Russia Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 89. Russia Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 90. Russia Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 91.
  • Figure 92. Russia Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 93. Netherlands Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 94. Netherlands Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 95. Netherlands Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 96. Netherlands Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 97. Netherlands Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 98. Netherlands Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 99. Netherlands Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 100. Netherlands Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 101. Spain Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Spain Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 103. Spain Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 104. Spain Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 105. Spain Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 106. Spain Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 107. Spain Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 108. Spain Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 109. Turkey Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. Turkey Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 111. Turkey Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 112. Turkey Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 113. Turkey Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 114. Turkey Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 115. Turkey Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 116. Turkey Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 117. Poland Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Poland Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 119. Poland Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 120. Poland Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 121. Poland Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 122. Poland Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 123. Poland Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 124. Poland Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 125. South America Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 126. South America Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 127. South America Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 128. South America Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 129. South America Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 130. South America Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 131. South America Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 132. South America Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 133. South America Infectious Disease Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 134. Brazil Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 135. Brazil Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 136. Brazil Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 137. Brazil Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 138. Brazil Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 139. Brazil Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 140. Brazil Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 141. Brazil Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 142. Argentina Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 143. Argentina Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 144. Argentina Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 145. Argentina Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 146. Argentina Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 147. Argentina Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 148. Argentina Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 149. Argentina Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 150. Asia-Pacific Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. Asia-Pacific Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 152. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 153. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 154. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 155. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 156. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 157. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 158. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 159. India Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 160. India Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 161. India Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 162. India Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 163. India Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 164. India Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 165. India Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 166. India Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 167. China Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. China Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 169. China Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 170. China Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 171. China Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 172. China Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 173. China Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 174. China Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 175. Japan Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Japan Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 177. Japan Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 178. Japan Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 179. Japan Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 180. Japan Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 181. Japan Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 182. Japan Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 183. Australia Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 184. Australia Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 185. Australia Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 186. Australia Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 187. Australia Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 188. Australia Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 189. Australia Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 190. Australia Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 191. Vietnam Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 192. Vietnam Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 193. Vietnam Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 194. Vietnam Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 195. Vietnam Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 196. Vietnam Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 197. Vietnam Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 198. Vietnam Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 199. South Korea Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 200. South Korea Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 201. South Korea Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 202. South Korea Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 203. South Korea Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 204. South Korea Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 205. South Korea Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 206. South Korea Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 207. Indonesia Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 208. Indonesia Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 209. Indonesia Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 210. Indonesia Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 211. Indonesia Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 212. Indonesia Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 213. Indonesia Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 214. Indonesia Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 215. Philippines Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 216. Philippines Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 217. Philippines Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 218. Philippines Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 219. Philippines Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 220. Philippines Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 221. Philippines Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 222. Philippines Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 223. Middle East & Africa Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 224. Middle East & Africa Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 225. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 226. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 227. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 228. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 229. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 230. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 231. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 232. Saudi Arabia Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 233. Saudi Arabia Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 234. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 235. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 236. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 237. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 238. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 239. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 240. UAE Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 241. UAE Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 242. UAE Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 243. UAE Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 244. UAE Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 245. UAE Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 246. UAE Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 247. UAE Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 248. South Africa Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 249. South Africa Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 250. South Africa Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 251. South Africa Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 252. South Africa Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
  • Figure 253. South Africa Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
  • Figure 254. South Africa Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
  • Figure 255. South Africa Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 256. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 257. By Sample Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 258. By Setting Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 259. By Type of Testing Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 260. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 261. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 262. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023